[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sun Pharma Japan Limited\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":48},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100640974","phase-3-study-to-evaluate-the-efficacy-and-safety-of-deuruxolitinib-in-japanese-adults-with-severe-alopecia-areata-100640974",false,"NCT07617597","Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata","A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adult Patients With Severe Alopecia Areata With an Open-Label Extension Period","THRIVE-AAJP","Inclusion Criteria:\n\n* Written informed consent has been obtained.\n* Japanese subjects with severe alopecia areata who are between 18 and 65 years of age, inclusive, at the time of informed consent.\n* Definitive diagnosis of alopecia areata with a current episode of scalp hair loss lasting at least 6 months.\n* SALT score of 50 or more at both Screening and Baseline.\n\nExclusion Criteria:\n\n* Treatment with systemic immunosuppressive medications or agents, including Janus kinase inhibitors, within 4 months prior to randomization.\n* Treatment with biologics within 6 months prior to Screening.\n* Positive test results for hepatitis B virus, hepatitis C virus, or human immunodeficiency virus at Screening.\n* History of active tuberculosis, a positive interferon gamma release assay at Screening, or evidence of tuberculosis-related lesions on chest radiography.\n* Clinically significant hematologic abnormalities, hepatic impairment, or renal impairment at Screening.","ALL","18 Years","65 Years",{"count":21,"type":22},78,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","This study evaluates the efficacy and safety of deuruxolitinib in Japanese Adults between 18 and 65 years of age who have 50% or greater scalp hair loss.",[28],"Alopecia Areata",[30,31,32,33,34],"alopecia areata","severe alopecia areata","hair loss","deuruxolitinib","JAK inhibitor","RECRUITING","2026-06-30",{"date":38,"type":39},"2026-07-02","ACTUAL",{"date":41,"type":39},"2026-06-19",{"date":43,"type":22},"2028-09",{"name":45,"class":46},"Sun Pharma Japan Limited","INDUSTRY",18,""]